PTC Therapeutics Inc
DUS:BH3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
DUS:BH3
|
US |
|
Z
|
Zijin Mining Group Co Ltd
XBER:FJZ
|
CN |
|
A
|
Adler Group SA
DUS:ADJ
|
LU |
|
C
|
Colgate-Palmolive Co
XBER:CPA
|
US |
|
M
|
Meta Platforms Inc
LSE:0QZI
|
US |
|
O
|
O'Reilly Automotive Inc
XBER:OM6
|
US |
|
MingZhu Logistics Holdings Ltd
NASDAQ:YGMZ
|
CN |
|
C
|
Cakra Buana Resources Energi PT Tbk
IDX:CBRE
|
ID |
|
T
|
Teradyne Inc
XBER:TEY
|
US |
|
S
|
Schneider Electric SE
LSE:0NWV
|
FR |
Wall St Price Targets
BH3 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BH3 is 72.58 EUR with a low forecast of 50.1 EUR and a high forecast of 107.64 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BH3's stock price target?
Price Target
72.58
EUR
According to Wall Street analysts, the average 1-year price target for BH3 is 72.58 EUR with a low forecast of 50.1 EUR and a high forecast of 107.64 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 2%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-4%
The compound annual growth rate for Operating Income over the next 8 years is -4%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 8 years is -3%.
